Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a randomised trial, infants living in a large village in The Gambia were immunised either at 4 months of age with 40,000 plaque forming units (PFU) of the Edmonston-Zagreb (EZ) measles vaccine or at the usual age of 9 months with 6000 TCID50 of a conventional Schwarz measles vaccine. Measles developed in 2 of 119 children who received the EZ vaccine, in 1 before and in the other after 9 months of age. In the Schwarz group measles developed in 7 of 120 children--in 5 before and in 2 after 9 months of age. Serological responses measured at 5 months after vaccination and at 18 months of age were satisfactory in both groups although in the Schwarz group levels were on average 2-fold higher than in the EZ group. The frequencies of fever, cough, vomiting, and diarrhoea were no higher in the EZ vaccinees in the 3 weeks following vaccination than in age-matched non-immunised controls. Long-term morbidity as assessed by clinic attendances and weight at 18 months of age was much the same in the two groups. The EZ measles vaccine is thus safe and clinically and serologically effective when used in a high dose to immunise young Gambian infants.

Original publication

DOI

10.1016/s0140-6736(88)92781-x

Type

Journal article

Journal

Lancet

Publication Date

08/10/1988

Volume

2

Pages

811 - 814

Keywords

Africa, Africa South Of The Sahara, Antibodies--analysis, Biology, Data Collection, Delivery Of Health Care, Demographic Factors, Developing Countries, Diseases, English Speaking Africa, Evaluation, Gambia, Health, Health Services, Immunity, Immunization, Immunologic Factors, Measles--prevention and control, Morbidity, Physiology, Population, Population Characteristics, Primary Health Care, Research Methodology, Rural Population, Vaccination--side effects, Viral Diseases, Western Africa, Age Factors, Antibodies, Viral, Antibody Formation, Clinical Trials as Topic, Drug Evaluation, Female, Gambia, Humans, Immunization Schedule, Infant, Measles, Measles Vaccine, Random Allocation, Urban Population, Vaccination